细菌素
生物
抗菌剂
基因组
计算生物学
失调
微生物群
药物发现
人体微生物群
抗菌肽
基因组
微生物学
基因
生物信息学
遗传学
作者
Sabu Thomas,Karthika Suryaletha,Akhila Velappan Savithri,Seema A. Nayar,Sijo Asokan,Divya Rajeswary
出处
期刊:Current Protein & Peptide Science
[Bentham Science]
日期:2022-10-20
卷期号:23 (12): 811-822
被引量:2
标识
DOI:10.2174/1389203724666221019111515
摘要
Abstract: The human microbiome is a reservoir of potential bacteriocins that can counteract with the multidrug resistant bacterial pathogens. Unlike antibiotics, bacteriocins selectively inhibit a spectrum of competent bacteria and are said to safeguard gut commensals, reducing the chance of dysbiosis. Bacteriocinogenic probiotics or bacteriocins of human origin will be more pertinent in human physiological conditions for therapeutic applications to act against invading pathogens. Recent advancement in the omics approach enables the mining of diverse and novel bacteriocins by identifying biosynthetic gene clusters from the human microbial genome, pangenome or shotgun metagenome, which is a breakthrough in the discovery line of novel bacteriocins. This review summarizes the most recent trends and therapeutic potential of bacteriocins of human microbial origin, and the advancement in the in silico algorithms and databases in the discovery of novel bacteriocin, and how to bridge the gap between the discovery of bacteriocin genes from big datasets and their in vitro production. Besides, the later part of the review discussed the various impediments in their clinical applications and possible solution to bring them in the frontline therapeutics to control infections, thereby meeting the challenges of global antimicrobial resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI